Change in vaccine vial monitor (VVM) assignment for GlaxoSmithKline Rotarix product

Language
Published
2017

This information bulletin addresses the implications and required guidance associated with the upcoming scheduled shift in vaccine vial monitor (VVM) of the GlaxoSmithKline Biologicals SA (GSK) Rotavirus vaccine, Rotarix®, from VVM type 14 (VVM14) to VVM type 7 (VVM7). The information below is intended for WHO/UNICEF staff, as well as Expanded Program for Immunization (EPI) managers or other partner agencies which support immunization programmes.